Drug patent expiry dates aren’t just legal milestones—they’re commercial deadlines. And most teams treat them like a back-office calendar item instead of a revenue strategy. The result? Missed windows, late launches, and competitors who show up first w…
Turn Drug Patent Expiry Dates Into Your Next Sales Campaign Read Post »
Sell the line before the patent breaks: a business development guide for solid-dose equipment suppliers targeting pre-LOE generic expansion
The most expensive mistake in pharma manufacturing isn’t buying the wrong machine. It’s arriving too late.
When …
The impact of Lyrica (pregabalin) on liver function is a topic of concern for individuals taking the medication. Lyrica is… https://www.Drugchatter.com/chat/26609/how-does-lyrica-affect-liver-function/
DrugChatter: How does lyrica affect liver function? Read Post »
The “Smarter Monopoly” Debate Is Here—and It’s About More Than Patents
Drug pricing isn’t just a policy argument anymore—it’s a design problem. And the design question at the center of today’s debate is deceptively simple: what should happen when a dru…
The Smarter Monopoly: Orphan Drug Exclusivity vs. Standard Drug Patents Read Post »
Sell Before the Cliff: A Business Development Playbook for Sterile Manufacturing Suppliers Targeting Biologic LOE
The market doesn’t wait for you to catch up.
If you’re a sterile manufacturing supplier serving biologics, the “cliff” is real: Loss of Ex…
The patent clock doesn’t just tick—it gets reset.
For years, the public conversation around drug pricing has focused on one villain: “bad patents.” But the more uncomfortable truth is that the system is often designed to outlast generic competition—n…
Patients aren’t asking “about patents.” They’re asking: “Will I be able to get my medicine?”
If you’ve spent any time reading what people search online, you’ll notice something striking: most “drug switching” questions aren’t really about chemistry or …
Drug Switching Questions: What Patients Are Really Asking Online Read Post »
Evergreening isn’t a rumor in pharma—it’s a playbook.
Brand teams don’t just defend their turf; they actively reshape it. New formulations, “minor” label expansions, device tweaks, manufacturing process changes, and patent thickets can extend exclusivi…
GPT, Rosalind, and the Generic Drug Question: What OpenAI’s Life Sciences Bet Really Changes
The hook: The most important part of OpenAI’s life sciences push may not be the model itself—it’s what it signals about how fast generic drug development could…
GPT-Rosalind and Generic Drugs: What OpenAI’s Life Sciences Model Actually Changes Read Post »
The patent cliff isn’t just a legal event—it’s a payer strategy deadline.
Most teams treat the “patent cliff” like a countdown to generic entry. But in payer-land, the clock starts earlier—and the winners aren’t always the ones with the best science. T…
Beat the Patent Cliff: How to Trigger Payer Strategy Campaigns Before Drug Patent LOE Read Post »
Get new actionable insights and updates from BiotechBlog
